To enable it to continue to meet steadily growing demand for its innovative new medicines, the Roche Group intends to expand its manufacturing capacity for biotechnology products. The company plans to construct a new biotech centre at the Group’s Basel campus and an additional facility at the Penzberg site in Germany. The projects, representing capital expenditures of about 400 million Swiss francs each, will take three years to complete. The new facilities will initially be used to manufacture the active ingredients of the anti-cancer medicines Avastin and Herceptin, both of which belong to a group of therapeutic agents known as monoclonal antibodies. To operate the new Basel and Penzberg facilities, Roche will be creating roughly 150 new jobs at each site.
